pioglitazone has been researched along with Prediabetic State in 41 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Prediabetic State: The time period before the development of symptomatic diabetes. For example, certain risk factors can be observed in subjects who subsequently develop INSULIN RESISTANCE as in type 2 diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a randomized, multicenter, 2 × 2 factorial designed study to examine whether intensive lifestyle intervention and/or pioglitazone could revert prediabetes to normal glucose tolerance." | 9.51 | A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes. ( Chang, C; Chen, W; Guo, X; Ji, L; Luo, Y; Paul, SK; Wang, H; Yang, J; Zhou, X, 2022) |
| "To analyze the effects of pioglitazone in patients with good adherence as well as intention-to-treat effects of pioglitazone in patients with prediabetes in the IRIS trial." | 9.30 | Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial. ( Dearborn-Tomazos, J; Ford, GA; Furie, KL; Gorman, M; Inzucchi, SE; Kernan, WN; Lovejoy, AM; Spence, JD; Viscoli, CM; Young, LH, 2019) |
| " The aim of the study was to evaluate whether dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin (ALO) alone or in combination with pioglitazone (PIO) improves β-cell function along with insulin resistance (IR) in metformin (MET) treated obese women with PCOS with persistent IR." | 9.24 | Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS. ( Goricar, K; Janez, A; Jensterle, M, 2017) |
| "To determine the efficacy and safety of long-term pioglitazone treatment in patients with NASH and prediabetes or T2DM." | 9.22 | Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. ( Bril, F; Cusi, K; Darland, C; Hardies, J; Hecht, J; Lomonaco, R; Musi, N; Orsak, B; Ortiz-Lopez, C; Portillo-Sanchez, P; Tio, F; Webb, A, 2016) |
| "While this study was too underpowered to determine the effect of pioglitazone, the result failed to show beneficial effects in patients of ischemic stroke or TIA with impaired glucose tolerance and newly diagnosed diabetes." | 9.20 | Effects of Pioglitazone for Secondary Stroke Prevention in Patients with Impaired Glucose Tolerance and Newly Diagnosed Diabetes: The J-SPIRIT Study. ( Furukawa, Y; Hattori, N; Kawamori, R; Miyamoto, N; Nakahara, T; Nakamura, S; Okuma, Y; Shimura, H; Tanaka, R; Tanaka, Y; Tomizawa, Y; Ueno, Y; Urabe, T; Watada, H; Yamashiro, K, 2015) |
| "This study examined the effects of pioglitazone on body weight and bone mineral density (BMD) prospectively in patients with impaired glucose tolerance as pioglitazone (TZD) increases body weight and body fat in diabetic patients and increases the risk of bone fractures." | 9.17 | Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial. ( Banerji, MA; Bray, GA; Buchanan, TA; Clement, SC; DeFronzo, RA; Henry, RR; Kitabchi, AE; Mudaliar, S; Musi, N; Ratner, RE; Reaven, PD; Schwenke, DC; Smith, SR; Stentz, FB; Tripathy, D, 2013) |
| "Maximal-dose pioglitazone had no effects on BMD or bone turnover, while improving glycemic control as expected, in postmenopausal women with impaired fasting glucose or impaired glucose tolerance." | 9.17 | Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. ( Bone, HG; Lindsay, R; McClung, MR; Perez, AT; Raanan, MG; Spanheimer, RG, 2013) |
| "To determine whether changes in standard and novel risk factors during the Actos Now for Prevention of Diabetes trial explained the slower rate of carotid intima media thickness (CIMT) progression with pioglitazone treatment in persons with prediabetes." | 9.17 | Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. ( Banerji, M; Bray, GA; Buchanan, TA; Clement, SC; DeFronzo, RA; Henry, RR; Hodis, HN; Kitabchi, AE; Mack, WJ; Mudaliar, S; Musi, N; Ratner, RE; Reaven, PD; Saremi, A; Schwenke, DC; Stentz, FB; Tripathy, D, 2013) |
| "To systematically evaluate the effects of pioglitazone in the treatment of patients with prediabetes or T2DM combined with NAFLD." | 9.12 | Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis. ( Fu, J; Lian, J, 2021) |
| " Use of pioglitazone in stroke patients with insulin resistance, prediabetes, and diabetes mellitus was associated with lower risk of recurrent stroke (hazard ratio 0." | 8.95 | Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis. ( Lee, M; Liao, HW; Lin, CH; Ovbiagele, B; Saver, JL, 2017) |
| "To evaluate the effect of pioglitazone in people with insulin resistance, pre-diabetes and type 2 diabetes." | 8.95 | Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. ( Chen, TH; Lee, M; Liao, HW; Ovbiagele, B; Saver, JL; Wu, YL, 2017) |
| "Two head-to-head RCTs of type 2 diabetes demonstrated significant improvements in A1c in both groups at follow-up with no significant difference between groups; a third study found no significant change in A1c in either group." | 6.44 | Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis. ( Carson, S; Norris, SL; Roberts, C, 2007) |
| "We conducted a randomized, multicenter, 2 × 2 factorial designed study to examine whether intensive lifestyle intervention and/or pioglitazone could revert prediabetes to normal glucose tolerance." | 5.51 | A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes. ( Chang, C; Chen, W; Guo, X; Ji, L; Luo, Y; Paul, SK; Wang, H; Yang, J; Zhou, X, 2022) |
| " Seventeen adult male cynomolgus macaques (Macaca fascicularis) were studied in a Latin square design such that all animals received 0, 1, 2, and 5 mg/kg pioglitazone for 6 weeks with 2 weeks of washout between dosing intervals." | 5.36 | Fluid compartmental shifts with efficacious pioglitazone therapy in overweight monkeys: implications for peroxisome proliferator-activated receptor-gamma agonist use in prediabetes. ( Berquist, ML; Brown, KK; Kavanagh, K; Wagner, JD; Zhang, L, 2010) |
| "Treatment with pioglitazone and rosiglitazone significantly decreased the AT(1)R specific binding in HFD fed rats." | 5.34 | PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance. ( Gaikwad, AB; Ramarao, P; Viswanad, B, 2007) |
| "Treatment of patients with prediabetes or T2DM with pioglitazone for up to 3 years was associated with decreased BMD at the level of the lumbar spine." | 5.30 | Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36-month clinical trial. ( Barb, D; Bril, F; Bruder, JM; Cusi, K; Lomonaco, R; Orsak, B; Portillo-Sanchez, P, 2019) |
| "To analyze the effects of pioglitazone in patients with good adherence as well as intention-to-treat effects of pioglitazone in patients with prediabetes in the IRIS trial." | 5.30 | Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial. ( Dearborn-Tomazos, J; Ford, GA; Furie, KL; Gorman, M; Inzucchi, SE; Kernan, WN; Lovejoy, AM; Spence, JD; Viscoli, CM; Young, LH, 2019) |
| " The aim of the study was to evaluate whether dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin (ALO) alone or in combination with pioglitazone (PIO) improves β-cell function along with insulin resistance (IR) in metformin (MET) treated obese women with PCOS with persistent IR." | 5.24 | Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS. ( Goricar, K; Janez, A; Jensterle, M, 2017) |
| "To determine the efficacy and safety of long-term pioglitazone treatment in patients with NASH and prediabetes or T2DM." | 5.22 | Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. ( Bril, F; Cusi, K; Darland, C; Hardies, J; Hecht, J; Lomonaco, R; Musi, N; Orsak, B; Ortiz-Lopez, C; Portillo-Sanchez, P; Tio, F; Webb, A, 2016) |
| "In IGT subjects, Quantose M(Q) parallels changes in insulin sensitivity and glucose tolerance with pioglitazone therapy." | 5.20 | A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study. ( Adam, KP; Banerji, M; Bray, GA; Buchanan, TA; Clement, SC; Cobb, JE; DeFronzo, RA; Ferrannini, E; Gall, W; George, T; Henry, RR; Kitabchi, AE; Mudaliar, S; Musi, N; Ratner, RE; Reaven, PD; Schwenke, DC; Stentz, FB; Tripathy, D, 2015) |
| "While this study was too underpowered to determine the effect of pioglitazone, the result failed to show beneficial effects in patients of ischemic stroke or TIA with impaired glucose tolerance and newly diagnosed diabetes." | 5.20 | Effects of Pioglitazone for Secondary Stroke Prevention in Patients with Impaired Glucose Tolerance and Newly Diagnosed Diabetes: The J-SPIRIT Study. ( Furukawa, Y; Hattori, N; Kawamori, R; Miyamoto, N; Nakahara, T; Nakamura, S; Okuma, Y; Shimura, H; Tanaka, R; Tanaka, Y; Tomizawa, Y; Ueno, Y; Urabe, T; Watada, H; Yamashiro, K, 2015) |
| "Maximal-dose pioglitazone had no effects on BMD or bone turnover, while improving glycemic control as expected, in postmenopausal women with impaired fasting glucose or impaired glucose tolerance." | 5.17 | Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. ( Bone, HG; Lindsay, R; McClung, MR; Perez, AT; Raanan, MG; Spanheimer, RG, 2013) |
| "This study examined the effects of pioglitazone on body weight and bone mineral density (BMD) prospectively in patients with impaired glucose tolerance as pioglitazone (TZD) increases body weight and body fat in diabetic patients and increases the risk of bone fractures." | 5.17 | Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial. ( Banerji, MA; Bray, GA; Buchanan, TA; Clement, SC; DeFronzo, RA; Henry, RR; Kitabchi, AE; Mudaliar, S; Musi, N; Ratner, RE; Reaven, PD; Schwenke, DC; Smith, SR; Stentz, FB; Tripathy, D, 2013) |
| "To determine whether changes in standard and novel risk factors during the Actos Now for Prevention of Diabetes trial explained the slower rate of carotid intima media thickness (CIMT) progression with pioglitazone treatment in persons with prediabetes." | 5.17 | Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. ( Banerji, M; Bray, GA; Buchanan, TA; Clement, SC; DeFronzo, RA; Henry, RR; Hodis, HN; Kitabchi, AE; Mack, WJ; Mudaliar, S; Musi, N; Ratner, RE; Reaven, PD; Saremi, A; Schwenke, DC; Stentz, FB; Tripathy, D, 2013) |
| "While there is no evidence that metabolic control reduces the risk of stroke, some families of antidiabetic drugs with vascular benefits have been shown to reduce these effects when added to conventional treatments, both in the field of primary prevention in patients presenting type 2 diabetes and high vascular risk or established atherosclerosis (GLP-1 agonists) and in secondary stroke prevention in patients with type 2 diabetes or prediabetes (pioglitazone)." | 5.12 | Stroke prevention in patients with type 2 diabetes or prediabetes. Recommendations from the Cerebrovascular Diseases Study Group, Spanish Society of Neurology. ( Alonso de Leciñana, M; Amaro, S; Arenillas, JF; Ayo-Martín, O; Castellanos, M; Freijo, M; Fuentes, B; García-Pastor, A; Gómez Choco, M; Gomis, M; López-Cancio, E; Martínez Sánchez, P; Morales, A; Palacio-Portilla, EJ; Rodríguez-Yáñez, M; Roquer, J; Segura, T; Serena, J; Vivancos-Mora, J, 2021) |
| "To systematically evaluate the effects of pioglitazone in the treatment of patients with prediabetes or T2DM combined with NAFLD." | 5.12 | Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis. ( Fu, J; Lian, J, 2021) |
| " Use of pioglitazone in stroke patients with insulin resistance, prediabetes, and diabetes mellitus was associated with lower risk of recurrent stroke (hazard ratio 0." | 4.95 | Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis. ( Lee, M; Liao, HW; Lin, CH; Ovbiagele, B; Saver, JL, 2017) |
| "To evaluate the effect of pioglitazone in people with insulin resistance, pre-diabetes and type 2 diabetes." | 4.95 | Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. ( Chen, TH; Lee, M; Liao, HW; Ovbiagele, B; Saver, JL; Wu, YL, 2017) |
| " Reversal of lipotoxicity with pioglitazone is associated with significant histological improvement, which occurs within 6 months and persists with continued treatment (or for at least 3 years) in patients with prediabetes or type 2 diabetes, holding potential to modify the natural history of the disease." | 4.93 | Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. ( Cusi, K, 2016) |
| " In this issue of the British Journal of Pharmacology, Collino and colleagues report that pioglitazone can reduce hepatic inflammation and insulin resistance in rats administered a high cholesterol and fructose diet." | 3.76 | Hepatic inflammation and insulin resistance in pre-diabetes - further evidence for the beneficial actions of PPAR-gamma agonists and a role for SOCS-3 modulation. ( Chatterjee, PK, 2010) |
| "The pre-diabetic treatment with pioglitazone, despite significant weight gain, completely prevents to develop diabetes and enhances beta cell function with preservation of islet cell changes." | 3.74 | The different mechanisms of insulin sensitizers to prevent type 2 diabetes in OLETF rats. ( Ahn, CW; Cha, BS; Choi, SH; Kim, DJ; Kim, SK; Lee, HC; Lee, YJ; Lim, SK; Zhao, ZS, 2007) |
| "Progression to type 2 diabetes in people at high risk of diabetes can be markedly reduced with interventions designed to correct underlying pathophysiological disturbances (ie, impaired insulin secretion and resistance) in a real-world setting." | 2.87 | Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES). ( Abdul-Ghani, M; Armato, JP; DeFronzo, RA; Ruby, RJ, 2018) |
| "Patients with nonalcoholic fatty liver disease have a high cardiovascular risk, but statins are rarely prescribed because of fear of hepatotoxicity." | 2.84 | Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial. ( Bril, F; Cusi, K; Hecht, J; Lomonaco, R; Orsak, B; Portillo Sanchez, P; Tio, F, 2017) |
| "Two head-to-head RCTs of type 2 diabetes demonstrated significant improvements in A1c in both groups at follow-up with no significant difference between groups; a third study found no significant change in A1c in either group." | 2.44 | Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis. ( Carson, S; Norris, SL; Roberts, C, 2007) |
| "Atorvastatin treatment (Group D) abolished PPHTg which became comparable to controls, pioglitazone treatment partially blunted PPHTg resulting in intermediate PPHTg." | 1.43 | Postprandial Hypertriglyceridemia Predicts Development of Insulin Resistance Glucose Intolerance and Type 2 Diabetes. ( Aggarwal, S; Aslam, M; Galav, V; Madhu, SV; Sharma, KK, 2016) |
| " Seventeen adult male cynomolgus macaques (Macaca fascicularis) were studied in a Latin square design such that all animals received 0, 1, 2, and 5 mg/kg pioglitazone for 6 weeks with 2 weeks of washout between dosing intervals." | 1.36 | Fluid compartmental shifts with efficacious pioglitazone therapy in overweight monkeys: implications for peroxisome proliferator-activated receptor-gamma agonist use in prediabetes. ( Berquist, ML; Brown, KK; Kavanagh, K; Wagner, JD; Zhang, L, 2010) |
| "Treatment with pioglitazone and rosiglitazone significantly decreased the AT(1)R specific binding in HFD fed rats." | 1.34 | PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance. ( Gaikwad, AB; Ramarao, P; Viswanad, B, 2007) |
| "Pioglitazone was mixed in rat chow fed to the diabetic treated group (0." | 1.31 | Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat. ( Kohno, M; Miyatake, A; Mizushige, K; Murakami, K; Noma, T; Ohmori, K; Tsuji, T, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (14.63) | 29.6817 |
| 2010's | 30 (73.17) | 24.3611 |
| 2020's | 5 (12.20) | 2.80 |
| Authors | Studies |
|---|---|
| Zheng, J | 1 |
| Chen, X | 1 |
| Wu, L | 1 |
| Zhou, Y | 1 |
| Wang, Z | 1 |
| Li, J | 1 |
| Liu, Y | 1 |
| Peng, G | 1 |
| Berggren, PO | 1 |
| Zheng, X | 1 |
| Tong, N | 1 |
| Luo, Y | 1 |
| Wang, H | 1 |
| Zhou, X | 1 |
| Chang, C | 1 |
| Chen, W | 1 |
| Guo, X | 1 |
| Yang, J | 1 |
| Ji, L | 1 |
| Paul, SK | 1 |
| Elkhatib, MAW | 1 |
| Mroueh, A | 1 |
| Rafeh, RW | 1 |
| Sleiman, F | 1 |
| Fouad, H | 1 |
| Saad, EI | 1 |
| Fouda, MA | 1 |
| Elgaddar, O | 1 |
| Issa, K | 1 |
| Eid, AH | 1 |
| Eid, AA | 1 |
| Abd-Elrahman, KS | 1 |
| El-Yazbi, AF | 1 |
| Fuentes, B | 1 |
| Amaro, S | 1 |
| Alonso de Leciñana, M | 1 |
| Arenillas, JF | 1 |
| Ayo-Martín, O | 1 |
| Castellanos, M | 1 |
| Freijo, M | 1 |
| García-Pastor, A | 1 |
| Gomis, M | 1 |
| Gómez Choco, M | 1 |
| López-Cancio, E | 1 |
| Martínez Sánchez, P | 1 |
| Morales, A | 1 |
| Palacio-Portilla, EJ | 1 |
| Rodríguez-Yáñez, M | 1 |
| Roquer, J | 1 |
| Segura, T | 1 |
| Serena, J | 1 |
| Vivancos-Mora, J | 1 |
| Lian, J | 1 |
| Fu, J | 1 |
| Obi, PO | 1 |
| Jensterle, M | 1 |
| Goricar, K | 1 |
| Janez, A | 1 |
| Cusi, K | 5 |
| Rotman, Y | 1 |
| Sanyal, AJ | 1 |
| Bril, F | 3 |
| Portillo Sanchez, P | 1 |
| Lomonaco, R | 3 |
| Orsak, B | 3 |
| Hecht, J | 2 |
| Tio, F | 2 |
| Portillo-Sanchez, P | 2 |
| Barb, D | 1 |
| Bruder, JM | 1 |
| Armato, JP | 1 |
| DeFronzo, RA | 5 |
| Abdul-Ghani, M | 1 |
| Ruby, RJ | 1 |
| Pantoni, L | 1 |
| Spence, JD | 1 |
| Viscoli, CM | 1 |
| Inzucchi, SE | 1 |
| Dearborn-Tomazos, J | 1 |
| Ford, GA | 1 |
| Gorman, M | 1 |
| Furie, KL | 1 |
| Lovejoy, AM | 1 |
| Young, LH | 1 |
| Kernan, WN | 1 |
| Bray, GA | 4 |
| Smith, SR | 1 |
| Banerji, MA | 2 |
| Tripathy, D | 4 |
| Clement, SC | 4 |
| Buchanan, TA | 4 |
| Henry, RR | 4 |
| Kitabchi, AE | 4 |
| Mudaliar, S | 4 |
| Musi, N | 5 |
| Ratner, RE | 3 |
| Schwenke, DC | 5 |
| Stentz, FB | 4 |
| Reaven, PD | 5 |
| Bone, HG | 1 |
| Lindsay, R | 1 |
| McClung, MR | 1 |
| Perez, AT | 1 |
| Raanan, MG | 1 |
| Spanheimer, RG | 1 |
| Maruthur, NM | 1 |
| Gribble, MO | 1 |
| Bennett, WL | 1 |
| Bolen, S | 1 |
| Wilson, LM | 1 |
| Balakrishnan, P | 1 |
| Sahu, A | 1 |
| Bass, E | 1 |
| Kao, WH | 1 |
| Clark, JM | 1 |
| Cobb, JE | 1 |
| Gall, W | 1 |
| Adam, KP | 1 |
| George, T | 1 |
| Banerji, M | 2 |
| Ferrannini, E | 1 |
| Cai, Y | 1 |
| Lydic, TA | 1 |
| Turkette, T | 1 |
| Reid, GE | 1 |
| Olson, LK | 1 |
| Tanaka, R | 1 |
| Yamashiro, K | 1 |
| Okuma, Y | 1 |
| Shimura, H | 1 |
| Nakamura, S | 1 |
| Ueno, Y | 1 |
| Tanaka, Y | 1 |
| Miyamoto, N | 1 |
| Tomizawa, Y | 1 |
| Nakahara, T | 1 |
| Furukawa, Y | 1 |
| Watada, H | 1 |
| Kawamori, R | 1 |
| Hattori, N | 1 |
| Urabe, T | 1 |
| Aslam, M | 1 |
| Aggarwal, S | 1 |
| Sharma, KK | 1 |
| Galav, V | 1 |
| Madhu, SV | 1 |
| Mayor, S | 1 |
| Koska, J | 1 |
| Yassine, H | 1 |
| Trenchevska, O | 1 |
| Sinari, S | 1 |
| Yen, FT | 1 |
| Billheimer, D | 1 |
| Nelson, RW | 1 |
| Nedelkov, D | 1 |
| Ntaios, G | 1 |
| Kent, TA | 1 |
| Ortiz-Lopez, C | 1 |
| Hardies, J | 1 |
| Darland, C | 1 |
| Webb, A | 1 |
| Espinoza, SE | 1 |
| Wang, CP | 1 |
| Lee, M | 2 |
| Saver, JL | 2 |
| Liao, HW | 2 |
| Lin, CH | 1 |
| Ovbiagele, B | 2 |
| Wu, YL | 1 |
| Chen, TH | 1 |
| Kavanagh, K | 1 |
| Brown, KK | 1 |
| Berquist, ML | 1 |
| Zhang, L | 1 |
| Wagner, JD | 1 |
| Asakura, M | 1 |
| Kim, J | 1 |
| Asanuma, H | 1 |
| Kitakaze, M | 1 |
| Chatterjee, PK | 1 |
| Rizza, S | 1 |
| Cardellini, M | 1 |
| Porzio, O | 1 |
| Pecchioli, C | 1 |
| Savo, A | 1 |
| Cardolini, I | 1 |
| Senese, N | 1 |
| Lauro, D | 1 |
| Sbraccia, P | 1 |
| Lauro, R | 1 |
| Federici, M | 1 |
| Saremi, A | 1 |
| Hodis, HN | 1 |
| Mack, WJ | 1 |
| Mizushige, K | 2 |
| Tsuji, T | 2 |
| Noma, T | 2 |
| Gaikwad, AB | 1 |
| Viswanad, B | 1 |
| Ramarao, P | 1 |
| Choi, SH | 1 |
| Zhao, ZS | 1 |
| Lee, YJ | 1 |
| Kim, SK | 1 |
| Kim, DJ | 1 |
| Ahn, CW | 1 |
| Lim, SK | 1 |
| Lee, HC | 1 |
| Cha, BS | 1 |
| Norris, SL | 1 |
| Carson, S | 1 |
| Roberts, C | 1 |
| Bourassa, MG | 1 |
| Berry, C | 1 |
| Murakami, K | 1 |
| Ohmori, K | 1 |
| Miyatake, A | 1 |
| Kohno, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparative Clinical Study to Evaluate the Possible Beneficial Effect of Empagliflozin Versus Pioglitazone on Non-diabetic Patients With Non-Alcoholic Steatohepatitis[NCT05605158] | Phase 3 | 56 participants (Anticipated) | Interventional | 2022-11-30 | Not yet recruiting | ||
| Physiology of Disease Prevention Observational Study in Clinical Practice[NCT03308773] | 5,000 participants (Anticipated) | Observational | 2009-01-05 | Enrolling by invitation | |||
| Insulin Resistance Intervention After Stroke (IRIS) Trial[NCT00091949] | Phase 3 | 3,876 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Pioglitazone Compared to Placebo on Bone Metabolism in Impaired Fasting Glucose, Postmenopausal Women for One Year of Treatment[NCT00708175] | Phase 4 | 156 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Actos Now for Prevention of Diabetes (ACT NOW)[NCT00220961] | Phase 3 | 602 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM).[NCT00994682] | Phase 4 | 176 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Efficacy, Safety and Mechanism of Action of Lanifibranor (IVA337) in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease[NCT03459079] | Phase 2 | 54 participants (Anticipated) | Interventional | 2018-08-14 | Recruiting | ||
| Effect of Low-Dose Pioglitazone in Patients With Nonalcoholic Steatohepatitis (NASH)[NCT04501406] | Phase 2 | 166 participants (Anticipated) | Interventional | 2020-12-15 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Fatal or non-fatal acute myocardial infarction or unstable angina (NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 206 |
| Placebo | 249 |
(NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 136 |
| Placebo | 146 |
(NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 206 |
| Placebo | 249 |
Change in modified mental status examination (3MS) score from baseline to exit. Theoretical range of 3MS scores is 0-100. Baseline scores ranged from 22-100. (NCT00091949)
Timeframe: Annual measures from baseline to exit (up to 5 years)
| Intervention | units on a scale (Mean) |
|---|---|
| Pioglitazone | 0.27 |
| Placebo | 0.29 |
(NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 73 |
| Placebo | 149 |
(NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 127 |
| Placebo | 154 |
(NCT00091949)
Timeframe: Up to 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 175 |
| Placebo | 228 |
Number of participants with confirmed (through an adjudication process) fractures during the study. Circumstances surrounding the fracture, available X-ray and other diagnostic results and healing status were collected for the adjudication process. (NCT00708175)
Timeframe: Up to 18 months.
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 1 |
| Placebo | 3 |
The change in bone mineral density in the total proximal femur at month 12 relative to baseline. DXA is a means of measuring BMD through x-ray. (NCT00708175)
Timeframe: Baseline and Month 12.
| Intervention | percent (Least Squares Mean) |
|---|---|
| Pioglitazone | -0.69 |
| Placebo | -0.14 |
The change in bone mineral density in the total proximal femur at month 18 relative to month 12. DXA is a means of measuring BMD through x-ray. (NCT00708175)
Timeframe: Month 12 and Month 18.
| Intervention | percent (Least Squares Mean) |
|---|---|
| Pioglitazone | -0.14 |
| Placebo | 0.04 |
The change between the fasting plasma glucose value collected at each time frame indicated. (NCT00708175)
Timeframe: Baseline and Month 12; Month 12 and Month 18.
| Intervention | mg/dL (Least Squares Mean) | |
|---|---|---|
| Baseline to Month 12 (n=57; n=61) | Month 12 to Month 18 (n=54; n=57) | |
| Pioglitazone | -2.8 | 0.4 |
| Placebo | 6.0 | -1.0 |
Participants were considered to have converted to T2DM if there were ≥2 consecutive post-Baseline FPG measurements ≥126 mg/dL. Participants meeting criteria were tabulated and summarized by Study Period (Treatment and Follow-up). Conversion to T2DM during Treatment Period occurred if either both of the consecutive post-Baseline high FPG values, or the first of the 2 consecutive high values occurred on or before the first day off study drug. Conversion to T2DM occurred during the Follow-up Period if both consecutive high values occurred after at least 1 day after the Treatment Period. (NCT00708175)
Timeframe: Up to 18 months.
| Intervention | participants (Number) | |
|---|---|---|
| Double-Blind Period (n=76; n=75) | Follow-up Period (n=63; n=59) | |
| Pioglitazone | 1 | 0 |
| Placebo | 7 | 1 |
Fasting Plasma Glucose (NCT00220961)
Timeframe: Baseline versus 2.4 years
| Intervention | mg/dl (Mean) |
|---|---|
| Placebo | -4.0 |
| Pioglitazone | -10.7 |
Insulin sensitivity The Matsuda index was calculated as 10,000/square root of (pre-meal glucose x pre-meal insulin x mean 120 min post-meal glucose x mean 120 min post-meal insulin), with higher numbers indicating better the insulin sensitivity. (NCT00220961)
Timeframe: Baseline versus 2.4 years
| Intervention | matsuda index (Mean) |
|---|---|
| Placebo | 0.7 |
| Pioglitazone | 3.6 |
Insulin secretion (NCT00220961)
Timeframe: Baseline versus 2.4 years
| Intervention | nmol (Mean) |
|---|---|
| Placebo | 35 |
| Pioglitazone | 25 |
carotid intima thickness (NCT00220961)
Timeframe: Baseline versus 2.4 years
| Intervention | percentage of intima (Mean) |
|---|---|
| Placebo | 1.7 |
| Pioglitazone | 3.2 |
Percentage of Participants with Type 2 Diabetes at 2.4 years Post-randomization (NCT00220961)
Timeframe: 2.4 years
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 16.1 |
| Pioglitazone | 5.0 |
Suppression of free fatty acids by low dose insulin (i.e., percentage of reduction of plasma FFA with low dose insulin infusion compared to the baseline state). This was calculated as: 100*((plasma FFA without insulin - plasma FFA with insulin infusion)/plasma FFA without insulin). All measurements are obtained at the same time point during an euglycemic insulin clamp. (NCT00994682)
Timeframe: 18 months
| Intervention | % of suppression of FFA (Mean) |
|---|---|
| Placebo | 46.1 |
| Pioglitazone | 65.9 |
Suppression of endogenous glucose production (Supp EGP) by low dose insulin (i.e., percentage of reduction of EGP with low dose insulin infusion compared to the baseline state). This was calculated as: 100*((EGP without insulin - EGP with insulin infusion)/EGP without insulin). All measurements are obtained at the same time point during an euglycemic insulin clamp. (NCT00994682)
Timeframe: 18 months
| Intervention | % of suppression of EGP (Mean) |
|---|---|
| Placebo | 37.7 |
| Pioglitazone | 55.3 |
Liver fat content was calculated as the fat fraction: 100*(area under the curve [AUC] of fat peak / [AUC of fat peak + AUC of water peak]). (NCT00994682)
Timeframe: 18 months
| Intervention | percentage of fat in liver (Mean) |
|---|---|
| Placebo | 11 |
| Pioglitazone | 7 |
"Number of patients with reduction of at least 2 points in the nonalcoholic fatty liver disease activity score (NAS) (with reduction in at least 2 different histological categories) without worsening of fibrosis. NAS is the sum of the separate scores for steatosis (0-3), hepatocellular ballooning (0-2) and lobular inflammation (0-3), and ranges from 0-8 .~The scoring system is based on the following grading:~Steatosis: 0 = <5%; 1 = 5-33%; 2 = >33-66%; 3 = >66%. Lobular Inflammation: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x. Hepatocyte Ballooning: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning. Fibrosis: 0 = None; 1 = Perisinusoidal or periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis." (NCT00994682)
Timeframe: At 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 9 |
| Pioglitazone | 29 |
Resolution of NASH was defined as absence of NASH after 18 months of therapy in patients with definite NASH (presence of zone 3 accentuation of macrovesicular steatosis of any grade, hepatocellular ballooning of any degree, and lobular inflammatory infiltrates of any amount) at baseline. (NCT00994682)
Timeframe: Month 18
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 10 |
| Pioglitazone | 26 |
Number of patients with osteoporotic fractures (NCT00994682)
Timeframe: 18 and 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pioglitazone | 0 |
| Placebo | 0 |
Rate of glucose disappearance (Rd) during high-dose insulin infusion. The rate of plasma glucose disappearance was calculated using Steele's non-steady-state equation. (NCT00994682)
Timeframe: 18 months
| Intervention | mg/kgLBM/min (Mean) |
|---|---|
| Placebo | 5.4 |
| Pioglitazone | 9.6 |
Total body fat measured by dual-energy x-ray absorptiometry (DXA) (NCT00994682)
Timeframe: Months 18
| Intervention | Percentage of body weight that is fat (Mean) |
|---|---|
| Placebo | 36 |
| Pioglitazone | 36 |
(NCT00994682)
Timeframe: Months 18 and 36
| Intervention | kg/m^2 (Mean) | |
|---|---|---|
| BMI Month 18 | BMI Month 36 | |
| Pioglitazone | 34.6 | 35.2 |
| Placebo | 34.6 | 36.7 |
Bone mineral density measured at the levels of spine, femoral neck, hip, and wrist by DXA. (NCT00994682)
Timeframe: 18 and 36 months
| Intervention | g/cm^2 (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Spine BMD at month 18 | Femoral Neck BMD at month 18 | Hip BMD at month 18 | Wrist BMD at month 18 | Spine BMD at month 36 | Femoral Neck BMD at month 36 | Hip BMD at month 36 | Wrist BMD at month 36 | |
| Pioglitazone | 1.04 | 0.84 | 1.05 | 0.76 | 1.06 | 0.84 | 1.02 | 0.75 |
| Placebo | 1.10 | 0.86 | 1.05 | 0.78 | 1.10 | 0.84 | 1.06 | 0.77 |
Homeostatic model assessment of insulin resistance (HOMA-IR) is a method for assessing insulin resistance (IR) from basal fasting plasma glucose (FPG) and fasting plasma insulin (FPI). It is calculated as (FPG x FPI)/405. (NCT00994682)
Timeframe: 18 and 36 months
| Intervention | Arbitrary units (Mean) | |
|---|---|---|
| HOMA-IR month 18 | HOMA-IR month 36 | |
| Pioglitazone | 1.4 | 1.6 |
| Placebo | 4.3 | 2.3 |
"Number of patients with improvement of at least 1 grade in each of the histological parameters.~Steatosis: 0 = <5%; 1 = 5-33%; 2 = >33-66%; 3 = >66%. Lobular Inflammation: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x. Hepatocyte Ballooning: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning. Fibrosis: 0 = None; 1 = Perisinusoidal or periportal, 1A = Mild, zone 3, perisinusoidal delicate fibrosis; 1B = Moderate, zone 3, perisinusoidal dense fibrosis; 1C = Portal/periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis" (NCT00994682)
Timeframe: Month 18
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Steatosis | Inflammation | Ballooning | Fibrosis | |
| Pioglitazone | 35 | 25 | 25 | 20 |
| Placebo | 13 | 11 | 12 | 13 |
(NCT00994682)
Timeframe: 18 and 36 months
| Intervention | U/L (Mean) | |||
|---|---|---|---|---|
| ALT at month 18 | AST at month 18 | ALT at month 36 | AST at month 36 | |
| Pioglitazone | 27 | 29 | 27 | 27 |
| Placebo | 44 | 38 | 32 | 30 |
Mean change in individual scores compared to baseline. Steatosis: 0 = <5%; 1 = 5-33%; 2 = >33-66%; 3 = >66%. Lobular Inflammation: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x. Hepatocyte Ballooning: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning. Fibrosis: 0 = None; 1 = Perisinusoidal or periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis (NCT00994682)
Timeframe: Baseline and Month 18
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Steatosis | Inflammation | Ballooning | Fibrosis | |
| Pioglitazone | -1.1 | -0.6 | -0.6 | -0.5 |
| Placebo | -0.2 | -0.1 | -0.2 | 0 |
Steatosis: 0 = <5%; 1 = 5-33%; 2 = >33-66%; 3 = >66%. Lobular Inflammation: 0 = No foci 1 = <2 foci/200x; 2 = 2-4 foci/200x, 3 = >4 foci/200x. Hepatocyte Ballooning: 0 = None; 1 = Few balloon cells; 2 = Many cells/prominent ballooning. Fibrosis: 0 = None; 1 = Perisinusoidal or periportal; 2 = Perisinusoidal and portal/periportal; 3 = Bridging fibrosis, 4 = Cirrhosis (NCT00994682)
Timeframe: Month 36
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Steatosis | Inflammation | Ballooning | Fibrosis | |
| Pioglitazone | 0.97 | 0.81 | 0.22 | 0.66 |
| Placebo | 1.56 | 1.30 | 0.33 | 0.89 |
(NCT00994682)
Timeframe: 18 and 36 months
| Intervention | μg/ml (Mean) | |
|---|---|---|
| Adiponectin month 18 | Adiponectin month 36 | |
| Pioglitazone | 22.8 | 24.2 |
| Placebo | 9.1 | 24.0 |
(NCT00994682)
Timeframe: 18 and 36 months
| Intervention | U/L (Mean) | |
|---|---|---|
| CK-18 month 18 | CK-18 month 36 | |
| Pioglitazone | 186 | 151 |
| Placebo | 314 | 245 |
Number of patients developing T2DM and number of patients regressing to NGT among patients with prediabetes (IFG/IGT). (NCT00994682)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Patients developing T2DM | Patients regressing to NGT | |
| Pioglitazone | 1 | 10 |
| Placebo | 2 | 1 |
8 reviews available for pioglitazone and Prediabetic State
| Article | Year |
|---|---|
Stroke prevention in patients with type 2 diabetes or prediabetes. Recommendations from the Cerebrovascular Diseases Study Group, Spanish Society of Neurology.
Topics: Diabetes Mellitus, Type 2; Humans; Neurology; Pioglitazone; Prediabetic State; Stroke | 2021 |
Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Pioglitaz | 2021 |
The pharmacogenetics of type 2 diabetes: a systematic review.
Topics: Acarbose; Biomarkers, Pharmacological; Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Humans; | 2014 |
Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Topics: Animals; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; I | 2016 |
Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Prediabeti | 2017 |
Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Edema; Fractures, Bone; Humans; Hypoglycemic Age | 2017 |
Pioglitazone: cardiovascular effects in prediabetic patients.
Topics: Animals; Aorta; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fibrosis; Humans; Hypoglycemic A | 2002 |
Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Pioglitazone; Prediabeti | 2007 |
14 trials available for pioglitazone and Prediabetic State
| Article | Year |
|---|---|
A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes.
Topics: Adult; Aged; Blood Glucose; China; Female; Follow-Up Studies; Glucose Tolerance Test; Humans; Hypogl | 2022 |
Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS.
Topics: Adult; Body Mass Index; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitor | 2017 |
Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Cardiovascular Diseases; Diabetes Mellitus, Type | 2017 |
Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36-month clinical trial.
Topics: Bone Density; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Non | 2019 |
Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES).
Topics: Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Hypoglyc | 2018 |
Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial.
Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Disease Progression; Female; Glycated Hemo | 2019 |
Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial.
Topics: Absorptiometry, Photon; Adipose Tissue; Body Mass Index; Body Weight; Bone Density; Diabetes Mellitu | 2013 |
Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study.
Topics: Adiposity; Aged; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; Bone Resorption; Double- | 2013 |
A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Glucose Toleranc | 2015 |
Effects of Pioglitazone for Secondary Stroke Prevention in Patients with Impaired Glucose Tolerance and Newly Diagnosed Diabetes: The J-SPIRIT Study.
Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Diabetes Mellitus, Type 2; Female; Glucose Intoleran | 2015 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Drug Administration Sche | 2016 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Drug Administration Sche | 2016 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Drug Administration Sche | 2016 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Drug Administration Sche | 2016 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Drug Administration Sche | 2016 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Drug Administration Sche | 2016 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Drug Administration Sche | 2016 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Drug Administration Sche | 2016 |
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Topics: Biomarkers; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Drug Administration Sche | 2016 |
Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance.
Topics: Adipokines; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Do | 2016 |
Pioglitazone improves endothelial and adipose tissue dysfunction in pre-diabetic CAD subjects.
Topics: Adiponectin; Adipose Tissue; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Male; Middl | 2011 |
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors.
Topics: Adiponectin; Adult; Aged; Biomarkers; Blood Glucose; Carotid Artery Diseases; Carotid Intima-Media T | 2013 |
19 other studies available for pioglitazone and Prediabetic State
| Article | Year |
|---|---|
Identification of MDM2, YTHDF2 and DDX21 as potential biomarkers and targets for treatment of type 2 diabetes.
Topics: Animals; Databases, Factual; Datasets as Topic; DEAD-box RNA Helicases; Diabetes Mellitus, Type 2; D | 2021 |
Amelioration of perivascular adipose inflammation reverses vascular dysfunction in a model of nonobese prediabetic metabolic challenge: potential role of antidiabetic drugs.
Topics: Adipose Tissue; Animals; Disease Models, Animal; Feeding Behavior; Hypoglycemic Agents; Inflammation | 2019 |
Can Pioglitazone Prevent or Delay Type 2 Diabetes in Patients with Prediabetes?
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Prediabetic State | 2021 |
Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver; Non-alcoholic Fatty Liver Disease; Pi | 2018 |
Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus-authors' response.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Pioglitaz | 2018 |
Potential New Horizons for the Prevention of Cerebrovascular Diseases and Dementia.
Topics: Cerebrovascular Disorders; Dementia; Humans; Pioglitazone; Prediabetic State; Stroke | 2019 |
Impact of alogliptin and pioglitazone on lipid metabolism in islets of prediabetic and diabetic Zucker Diabetic Fatty rats.
Topics: Animals; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Islets of Langerhans; Lipid Metabolis | 2015 |
Postprandial Hypertriglyceridemia Predicts Development of Insulin Resistance Glucose Intolerance and Type 2 Diabetes.
Topics: Animals; Atorvastatin; Blood Glucose; Body Weight; Causality; Diabetes Mellitus, Type 2; Dietary Fat | 2016 |
Pioglitazone may reduce cardiovascular events in high risk patients with prediabetes.
Topics: Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Prediabetic State; Stroke; Thiazol | 2016 |
Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes.
Topics: Adolescent; Adult; Aged; Apolipoprotein C-III; Diabetes Mellitus, Type 2; Female; Glycosylation; Hep | 2016 |
Insulin Resistance Intervention After Stroke Trial of Pioglitazone: Is This Perhaps the End of the Beginning?
Topics: Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; PPAR gamma; Prediabetic State; Stroke | 2016 |
Pioglitazone for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Pioglitaz | 2016 |
Fluid compartmental shifts with efficacious pioglitazone therapy in overweight monkeys: implications for peroxisome proliferator-activated receptor-gamma agonist use in prediabetes.
Topics: Absorptiometry, Photon; Animals; Blood Glucose; Body Composition; Body Water; Dose-Response Relation | 2010 |
[Anti-diabetic drugs for secondary prevention of cardiovascular disease in mild diabetic and IGT patients: ABC study and PPAR study].
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Metabolic Syndrome; P | 2010 |
Hepatic inflammation and insulin resistance in pre-diabetes - further evidence for the beneficial actions of PPAR-gamma agonists and a role for SOCS-3 modulation.
Topics: Animals; Hepatitis; Humans; Hypoglycemic Agents; Inflammation Mediators; Insulin; Insulin Resistance | 2010 |
PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance.
Topics: Angiotensin II; Animals; Aorta, Thoracic; Blood Pressure; Dietary Fats; Disease Models, Animal; Dose | 2007 |
The different mechanisms of insulin sensitizers to prevent type 2 diabetes in OLETF rats.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Metformin; Pioglita | 2007 |
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.
Topics: Antihypertensive Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Melli | 2008 |
Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat.
Topics: Animals; Blood Glucose; Collagen; Diabetes Mellitus, Type 2; Diastole; Echocardiography, Doppler; He | 2001 |